A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Public ClinicalTrials.gov record NCT07227831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Study identification
- NCT ID
- NCT07227831
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2026
- Primary completion
- May 21, 2027
- Completion
- May 21, 2028
- Last update posted
- Aug 25, 2026
2026 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 1
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Karmanos Cancer Institute at McLaren Bay Region | Bay City | Michigan | 48706 | Recruiting |
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston | Michigan | 48346 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint | Michigan | 48532 | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer | Michigan | 48446 | Recruiting |
| Karmanos Cancer Institute at McLaren Macomb | Mount Clemens | Michigan | 48043 | Recruiting |
| Karmanos Cancer Institute at McLaren Northern | Petoskey | Michigan | 49770 | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron | Michigan | 48060 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227831 live on ClinicalTrials.gov.